Hyperfine Temettü

Temettü kriter kontrolleri 0/6

Hyperfine does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

-0.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.3%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Hyperfine appoints Maria Sainz as President, CEO

Oct 06

Hyperfine GAAP EPS of -$0.33 misses by $0.06, revenue of $1.53M misses by $0.47M

Aug 10

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if HYPR's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if HYPR's dividend payments have been increasing.

Piyasaya Karşı Temettü Getirisi

Hyperfine Piyasaya Karşı Temettü Getirisi

HYPR temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (HYPR)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Medical Equipment)	1.7%
Analist tahmini (HYPR) (3 yıla kadar)	n/a

Önemli Temettü: Unable to evaluate HYPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate HYPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate HYPR's payout ratio to determine if its dividend payments are covered by earnings.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as HYPR has not reported any payouts.

Hyperfine Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Hyperfine, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Hyperfine, Inc. Revises Revenue Guidance for the Year 2024

Hyperfine, Inc. Revises Revenue Guidance for the Year 2024

Hyperfine Announces Presentation of Initial Data from Observational Clinical Studies Evaluating the Use of Portable MR Brain Imaging for Alzheimer's Patients

Hyperfine, Inc. Announces FDA Clearance of Software Update That Enables Faster Acquisition of Best-In-Class Ultra-Low-Field Brain Images

Hyperfine, Inc. Highlights Positive Results from Multi-Site Observational Study on Swoop® System for Stroke Assessment

Hyperfine, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Hyperfine Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Inclusion on the Nasdaq Global Market

Hyperfine, Inc. Provides Earnings Guidance for the Year 2024

Hyperfine, Inc. to Report Q1, 2024 Results on May 13, 2024

Hyperfine, Inc., Annual General Meeting, Jun 11, 2024

Hyperfine, Inc. Enroll First Alzheimer's Patients Receiving Amyloid-Targeting Therapy in Care PMR Study

Hyperfine, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Hyperfine, Inc. Launches AI-Powered Brain Imaging Software for Enhanced Image Quality and Ease of Use

Hyperfine, Inc. Provides Earnings Guidance for the Full Year 2023

Hyperfine, Inc. Completes Enrollment for Hope Pmr Pediatric Hydrocephalus Study Using Hyperfine, Inc. Portable Mr. Imaging System

Hyperfine, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Hyperfine, Inc. Announces Executive Changes

Hyperfine, Inc. Provides Earnings Guidance for the Year 2023

Hyperfine, Inc. Announces FDA Clearance for Improved AI-Powered Software and Expanded Field of View for the Swoop Portable MR Imaging System

Hyperfine, Inc. Announces New Data Regarding the Use of the Swoop System in Stroke Patient Follow-Up

Hyperfine, Inc. Announces Chief Financial Officer Changes

Hyperfine, Inc. Announces Termination of Neela Paykel as General Counsel, Chief Compliance Officer, and Corporate Secretary

Hyperfine Notifies the Nasdaq Listing Qualifications Staff

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Hyperfine, Inc. Provides Revenue Guidance for the Full Year of 2022

Hyperfine, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Hyperfine Names Maria Sainz as Chief Executive Officer, Effective October 24, 2022

Hyperfine appoints Maria Sainz as President, CEO

Consensus forecasts updated

Founder & Vice Chairman recently bought US$442k worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Hyperfine, Inc. Provides Revenue Guidance for the Full Year of 2022

Hyperfine GAAP EPS of -$0.33 misses by $0.06, revenue of $1.53M misses by $0.47M

Hyperfine, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Hyperfine, Inc. Announces Zero Radiation Dose Rapid MR Imaging Test for Pediatric Hydrocephalus Patients

Hyperfine, Inc. Announces Executive Changes, Effective July 29, 2022

Hyperfine stock plunges 14% as CEO Dave Scott steps down

Founder & Vice Chairman recently bought US$119k worth of stock

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Hyperfine, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

Hyperfine, Inc., Annual General Meeting, Jun 08, 2022

Hyperfine, Inc. to Report Q1, 2022 Results on May 11, 2022

Hyperfine (NASDAQ:HYPR) Is In A Good Position To Deliver On Growth Plans

Hyperfine: MR Imaging In A Swoop

Hyperfine, Inc. to Report Q4, 2021 Results on Mar 23, 2022

Hyperfine Appoints Chip Truwit, M.D. as Senior Medical Director

Hyperfine, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Hyperfine, Inc. announced a financing transaction

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin